LLY Eli Lilly and Co
- 867.000
- +9.530+1.11%
Eli Lilly and Co News
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics.AnaptysBio has a pipeline of checkpoint
The S&P 500 Typically Outperforms in July, Underperforms August-October - RBC Capital Markets
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
The race to develop oral weight loss medications is intensifying as companies like Roche Holdings AG (OTC:RHHBY), Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE)
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
By Adam Clark Eli Lilly and Novo Nordisk are sitting pretty in the pharmaceutical sector due to their weight-loss drugs. While the market has been nervous about potential competition, investors can
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Up to 20% weight loss! Eli Lilly and Co's Theralogix (Tesofensine) approved in China, stronger effect than Sibutramine?
Is the competition intensifying?
Kamala Harris' Potential Impact on Health Care Stocks
With President Joe Biden earlier Sunday saying he will end his campaign for re-election and endorsing Vice President Kamala Harris, the focus now turns on her positions on issues.
The Race to Develop the 'Holy Grail' of Weight-loss Drugs
Here Are Big Pharma's Leading Blockbuster Makers
Eli Lilly (NYSE:LLY) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too
US stocks closed with all three major indices falling, with the S&P Nasdaq index seeing its largest weekly decline in three months. Technology stocks weakened, with Tesla down more than 4%, Nvidia down more than 2%, and CrowdStrike down more than 11%.
Investors accelerated their escape from technology stocks, with stocks and bonds in Europe and the United States being hit hard for two days. This week, the S&P 500 and Nasdaq fell by about 2% and 3.7%, respectively. The Nasdaq stopped its six-week continuous rise, while the Dow and small-cap indices rose by 0.7% and 1.7%, respectively. Chip stocks fell more than 3% on Friday and nearly 9% for the week. Nvidia also fell more than 8.7% for the past three months, making it the worst performer. The "seven sisters of technology" all fell for the week, and cybersecurity leader Crowdstrike, which triggered a global technology outage, fell 11% on Friday, the worst in nearly two years. The VIX panic index rose more than 32% for the week.
Express News | Benzinga Market Summary: Microsoft And Airlines Outages Linked To Crowdstrike, Crowdstrike Opens Down Over 13%, Eli Lilly Rises After Zepbound Chinese Approval
Express News | Eli Lilly Shares Are Trading Higher After Zepbound Received China Approval
Today's Analyst Rating | Apple Price Target Raised to $260 by Melius Research, CFRA Upgrades Microsoft to Buy
Jul 19, Wall Street analysts have updated their stock ratings today including $Apple(AAPL.US)$ and $Microsoft(MSFT.US)$.
Eli Lilly and Company (LLY) Is Attracting Investor Attention: Here Is What You Should Know
HSBC Raises Price Target on Eli Lilly to $1,100 From $880, Maintains Buy Rating
Eli Lilly and Company (LLY) has an average rating of outperform and price targets ranging from $540 to $1,100, according to analysts by Capital IQ.Price: 866.65, Change: +17.75, Percent Change: +2.09
Eli Lilly and Co (LLY.US) weight-loss drug has been approved in China and will directly compete with Novo Nordisk (NVO.US).
Eli Lilly and Co (LLY.US) has obtained approval from the National Medical Products Administration (NMPA) for long-term weight management indications of Trulicity (dulaglutide) injection.
Express News | Eli Lilly Shares up 2.3% Premarket After Co's Weight Loss Drug Gets Approval in China
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
On Friday, China's National Medical Products Administration approved Eli Lilly And Co Tirzepatide for long-term weight management.
Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ
By David Wainer The two dominant players in the obesity market will eventually make way for a few more competitors. Just don't expect the latecomers to be equals to Eli Lilly and Novo Nordisk. There
Analysis
Price Target
No Data
